Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

No data are available from a valid guideline-compliant assessment on the potential for 2,3 dichloro-1,3 butadiene to induce delayed contact hypersensitivity. Furthermore, there are no indications of dermal sensitisation following repeated whole body inhalation exposures to 2,3 dichloro-1,3 butadiene. Although it is unlikely that 2,3 dichloro-1,3 butadiene potentiates delayed contact hypersensitivity based on observations from these studies, there are no information available to determine quantifiably whether 2,3 dichloro-1,3 butadiene is a potential skin sensitiser. Limited information from a study of the repeated topical administration of 2,3 dichloro-1,3 butadiene to ten guinea pigs suggests that no skin sensitisation was apparent. However the information is inadequate for a valid assessment of sensitising potential. Since 2,3 dichloro-1,3 butadiene is flammable, topical application is not a feasible method for determining contact sensitisation and precludes intra-dermal injection of the material on animal welfare grounds. 


Migrated from Short description of key information:
No evidence of skin or respiratory sensitisation was been observed in limited studies in guinea pigs or in whole body inhalation studies in rats. There is insufficient evidence to classify 2,3 dichloro-1,3 butadiene as either a dermal or a respiratory sensitiser.

Justification for classification or non-classification

Insufficient evidence to classify DCBD as either a dermal or respiratory sensitiser